ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

Joint Symposium on Medicinal Chemistry

 Boston, MA, United States    June 10-13, 2023

Scientific Program


Optional excursions

15:00

Registration

Opening Session

17:30

Opening of the Symposium and Welcome address

Prof. Daniel HARKI
UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States
17:45

PL01- Medicinal Chemistry, Trends, Targets and Technologies

Dr Klaus URBAHNS
MERCK KGAA, Darmstadt, Germany
18:30

Welcome Reception

08:00

Registration

Session 1 - Chemical Modulation of RNA

Session chair

Dr Darby SCHMIDT
SONATA THERAPEUTICS, Cambridge, United States
09:00

IL01 - Modulating the Conformation and Function of Disease-Relevant RNA with Small Molecules

Prof. Amanda HARGROVE
DUKE UNIVERSITY, Durham, NC, United States
09:30

IL02 - Targeting Non-Coding RNAs Using Synthetic Small Molecules: Original Targets for Innovative Therapies

Dr Maria DUCA
UNIVERSITY OF CÔTE D'AZUR, Nice, France
10:00

IL03 - Discovery and Development of Selective Splicing Modifiers as Therapeutics

Dr Matthew WOLL
PTC THERAPEUTICS, South Plainfield, NJ, United States
10:15

OC01

10:30

Coffee break & Exhibition

Session 2 - Advances in Targeted Protein Degradation

Session chair

Prof. Terry MOORE
UNIVERSITY OF ILLINOIS, Chicago, IL, United States
11:00

IL04 - Ligand Directed Degradation: from Proof-of-Concept Degradation to Clinical Studies

Dr Deborah MORTENSEN
BRISTOL MYERS SQUIBB, San Diego, CA, United States
11:30

IL05 - Chemical Biology Studies of the Thalidomide-Binding Domain of Cereblon

Prof. Christina WOO
HARVARD UNIVERSITY, Cambridge, MA, United States
12:00

OC02

12:15

OC03

12:30

Lunch & Exhibition

Session 3 - Proximity-inducing Molecules and their Therapeutic Applications

Session chair

Dr Amit CHOUDHARY
THE BROAD INSTITUTE, Cambridge, MA, United States
14:00

IL06 -Chemoproteomic-Enabled Development of Proximity-Inducing Molecules

Dr Christopher PARKER
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States
14:30

IL07 - An Intramolecular Bivalent Degrader Glues an Intrinsic BRD4-DCAF16 Interaction

Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
15:00

OC04

15:15

OC05

15:30

Coffee break & Exhibition

16:00

PL02 - RIPTACs: A New ‘Hold and Kill’-based Therapeutic Modality

Prof. Craig CREWS
YALE UNIVERSITY, New Haven, CT, United States
16:45

Poster session 1 (odd numbers)

18:00

End of the day

Session 4 - Drug Targets in GPCR Signaling

Session chair

Prof. György KESERU
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary
09:00

IL08 - New Hot Targets? Medicinal Chemistry of G Protein-Coupled Receptors Involved in Immunity and Cancer

Prof. Christa MÜLLER
UNIVERSITY OF BONN, Bonn, Germany
09:30

IL09 - Frontier SBDD accross the Orthosteric and Allosteric GPCRome

Dr Chris DE GRAAF
SOSEI HEPTARES, Cambridge, United Kingdom
10:00

OC06

10:15

OC07

10:30

Coffee break & Exhibition

Session 5 - Organic Synthesis Impacting Medicinal Chemistry & Chemical Biology

Session chair

Prof. Rui MOREIRA
UNIVERSITY OF LISBON, Lisbon, Portugal
11:00

IL10 - Photocatalysis in the Pharmaceutical Industry: Synthesis under a New Light

Dr Giulia BERGONZINI
ASTRAZENECA, Gothenburg, Sweden
11:30

IL11 - HTE Chemistry to Accelerate Medicinal Chemistry Programs

Dr Fabio LIMA
NOVARTIS, Basel, Switzerland
12:00

OC08

12:15

OC09

12:30

Lunch & Exhibition

Session 6 - Enabling Chemistries for Chemical Biology Research

Session chair

Prof. Daniel HARKI
UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States
14:00

IL12 - Chemical Probes Enabling Drug Target Discovery and Validation

Prof. Edward TATE
IMPERIAL COLLEGE LONDON, London, United Kingdom
14:30

IL13 - Generating Stem-Like T Cells with Small-Molecule Modulators for Cancer Immunotherapy

Prof. Peng WU
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States
15:00

OC10

15:15

OC11

15:30

Coffee break & Exhibition

16:00

PL03 -Carbohydrates in Health and Disease

Prof. Laura KIESSLING
MIT, Cambridge, MA, United States
16:45

Poster session 2 (even numbers)

Session 7 - A Focus on Early Career Investigators

Session chair

Dr Melissa GRENIER-DAVIES
GLAXOSMITHKLINE, Cambridge, MA, United States
09:00

IL14 - E3 Ligase Ligand Discovery for TPD

Dr Benika PINCH
NOVARTIS, Cambridge, MA, United States
09:15

IL15 - Chemical Approaches to Enhance Cellular Immunotherapies

Dr Mark P. FARRELL
UNIVERSITY OF KANSAS, Lawrence, KS, United States
09:30

IL16 - Machine Learning Tools to Accelerate Chemical Biology Studies

Dr Tiago RODRIGUES
UNIVERSITY OF LISBON, Lisbon, Portugal
09:45

OC12

10:00

OC13

10:15

OC14

10:30

Coffee break & Exhibition

Session 8 - Approaches to Identify and Target Cryptic and Allosteric Pocket

Session chair

Dr Malin LEMURELL
ASTRAZENECA, Gothenburg, Sweden
11:00

IL17 - A Computation-First Approach to Drug Challenging Disease Targets

Dr Woody SHERMAN
PSIVANT THERAPEUTICS, Boston, MA, United States
11:30

IL18 - X-ray Crystallographic Fragment Screening for the Identification of Allosteric binding Sites

Dr Andrew WOODHEAD
ASTEX THERAPEUTICS, Cambridge , United Kingdom
12:00

OC15

12:15

OC16

12:30

Lunch & Exhibition

Session 9 - Getting Out of the Starting Block: New Hit Finding and Chemotype Advancement Methods

Session chair

Dr Carolyn DZIERBA
BRISTOL-MYERS SQUIBB, Cambridge, United States
14:00

IL19 - RAPID – a Next-Generation Chemoproteomics Technology Enabling the Discovery of Reversible Binders to Pre-specified Targets in Living Cells

Dr Justin RETTENMAIER
JNANA THERAPEUTICS, Boston, MA, United States
14:30

IL20 - Covalent Fragment-Based Drug Discovery

Dr Daniel ERLANSON
FRONTIER MEDICINES, South San Francisco, CA, United States
15:00

IL21 - Large-scale in Silico Fragment Screening of ~200 Million Fragments Based on Absolute Free Energy Perturbation

Dr Eric THERRIEN
SCHRODINGER, New York, NY, United States
15:15

OC17

16:00

End of the Symposium